From my perspective and IMO, Where are we going? What is

New Post Public Reply Private Reply Replies (4) Message Board
MGK_2
728
From my perspective and IMO, Where are we going? What is all this leading to?
When Amarex begins to draw to a close, to a conclusion, some of Big Pharma will become more comfortable with CytoDyn, with Leronlimab. Big Money like Blackrock and Vanguard becomes more comfortable with going long CYDY and not so head long on shorting it. Big Media begin producing pro-CYDY articles and report factual, non-distortive information on CytoDyn and Leronlimab. The FDA approves Leronlimab.



When Amarex resolves, the FDA is comfortable with CytoDyn and many Big Pharma approach CytoDyn wanting to partner. They see Leronlimab's capacity to augment the functionality of their drug and ask CytoDyn to consider combination therapy for their indication. This becomes Big Pharma's only chance in escalating their drugs to the next level in the new era of enlightenment. Otherwise, they fail. Partnership with CytoDyn, in combination therapy with Leronlimab becomes their saving grace.

//

Given that Amarex is arbitration, it shouldn't go on for years. I'm giving it about a year from when it began, to about November or December, 2022. But it is very complicated. I don't know how deep Sidley Austin wants to take this. I don't know how much of a settlement they will be happy with. I don't know how easy are the pickins. I don't feel they will be happy with settling for less than a billion, so they may drag it on until they can get that, but I don't think they will continue to pursue the matter so long to extract its full worth of probably $20 billion.

So far so good. No discussion that arbitration is off course, therefore, I put it on course. Justice must be done. Judgement is coming. SA won't stop till justice comes to pass. The conclusion of the Amarex arbitration brings about a new era in pharmaceutical therapy, LL approval, FDA clearance and multiple BP partnerships in combination with Leronlimab.

//

What is Justice? Who did wrong? Was it only Amarex? Who collaborated with them? Will another pharmaceutical be implicated? Will Big Money be implicated? Will anyone rat on the other? Will anyone stand for CytoDyn? Will anyone agree that the BLA was sabotaged? Will anyone testify that the trials were botched or poorly documented? Will anyone bring about these details and clearly reveal what actually happened? Will the outcome of the Amarex arbitration set the record straight? What will be the main outcome after this arbitration is resolved? Would it be to reveal that Amarex was a pitiful CRO who couldn't write a BLA to save its life? (I think not.) or Would it be to reveal how a certain Pharma or a group of Pharmaceuticals and/or Big Money fear the FDA approval of Leronlimab given a successful combination trial of LL with HAART for HIV, with a p value of 0.0032.

From Wiki:
Quote:
In the pivotal trial of Leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients, 81% of patients completing trial achieved HIV viral load suppression of < 50 cp/mL. (where as ONLY with) Recent approved drugs for this population range from ONLY 43% after 24 weeks to ONLY 45% after 48 weeks with viral load suppression of < 50 cp/mL.


CytoDyn knew they had this in the bag. Everything had been lined up. Manufacturing. Salesforce. Distribution. Even Amarex said they will have the BLA submitted on time.

The only way this Big Entity had to block the approval of LL was to trip up the third part of this BLA submission and how else to do that but by sabotaging the BLA by colluding with the entity writing the Document who was the CRO, Amarex. How did they get the CRO/Amarex to submit a pathetic and cringeworthy document?

All of this is what Sidley Austin is set out to determine. How long will this drag out? What are the consequences if these multiple factions and entities do not oblige Sidley Austin? Delays and delays and it depends on the interactions between the entities involved. Some will push to get this resolved. I feel it will finish near end of year 2022.

Who put up the necessary $6.5 million bond to carry this arbitration out? David Welch put up this bond, out of his confidence and conviction in the matter. Whoever or whatever group/entity it was that colluded with Amarex to commit this deed against us, it should always be remembered that it was David Welch that has prevented this entity from doing it to us again, because, it will never happen again as a result of this arbitration which he stood for.

//

The addition of Dr. Paul Edison, Dr. Kabir Mody, Dr. Otto Yang and Dr. Jacob Lalazari, which potential CEO candidate would not be proud of such a list of experts to help him make his decisions? Doesn't the addition of this team of experts facilitate the search for an experienced and qualified CEO?

What if Amarex arbitration conclusion and the new CEO come together? I already said FDA comfort zone comes with Amarex concluding and then compounding that with a new qualified CEO... what do you have? CytoDyn grows big because many Big Pharma will have no chance without LL. Who ever is not against us is for us. Many will choose to join us. Yet, many will choose to fight this war with old tactics of deceit and usury, paying off the approving party for rapid approval, using inept, sub-par weapons of partial effectiveness, using all they and whatever they have and whoever would help them to beat us, still yet employing big money & big media but proving futile; however, many will leave those tactics and will rather choose a better way, leading to their success and to ours. Yes, the battles will continue.

//

You will have no need to be told that the times for CytoDyn have changed. It will be crystal clear. With the ending of Amarex and the completion of our board with new CEO, a new era begins in pharmaceutical treatments. A revelation will come over the people of the massive deceit which goes on in this industry. An understanding of the corruption and greed will grow. Clear evidence of clean effectual medicine being purposely thwarted and hindered pervades the atmosphere, the air waves. Understanding of disease pathways and mechanism of actions that confuse and render those diseases as inconsequential becomes paramount. People will wake the flapjacks up, people will become wiser. You will see this happen. Many companies are persuaded and pursue the ways of the people. They begin to pursue this new found understanding. But, many will hold fast to the old ways. But a division will be clear as day. A new age approaches and I feel humanity will survive it with CytoDyn leading, while Big Pharma and all of the other Bigs wither away, diminishing in battle.

1

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fermaca and NVIDIA Join Forces for AI Revolution

Updated Category News Views 24

When you think about AI these days, visions of sleek robots and endless data streams might crowd the brain. What Fermaca's teasing out in Mexico, though, ain't no sci-fi dream. They're yanking AI tech out of the clouds and plugging it straight into the ground, partnering with NVIDIA to make it happen. A Fresh Model on Familiar Grounds Fermaca, now rocking the badge of...

Continue Reading
Illinois House Democrats Surge with Historic Gaines

Updated Category News Views 79

Turning the Election Tide in Illinois Damn, if you're not paying attention to what's shaking in Illinois, it's time to listen up. The Democrats under Speaker Emanuel "Chris" Welch are strutting their stuff, leaving an indelible mark on the political landscape. An eye-popping $35 million in campaign dough was raised, safeguarding every Democratic incumbent and managing to...

Continue Reading
Saga Metals Advances Radar Project with HQ Drill Success

Updated Category News Views 95

Digging Deep at Trapper North: Saga's Strategic Drill Move There's nothing like the thrill of discovery, especially in the rough-and-tumble world of mining exploration. Saga Metals Corp., anchored deep in the critical minerals scene, has wrapped up an HQ-diameter drill program at its Radar Project, smack dab near Cartwright, Labrador. You hear 1,010 meters and maybe...

Continue Reading
Webull's Legal Woes: Shareholder Class Action Heats Up

Updated Category News Views 60

Webull's Legal Storm: What's Behind the Class Action? Here's a tale as old as time in the wild world of the stock market: a company paints a rosy picture, investors follow the trail, and when the curtain lifts, the scenery looks starkly different. Enter Webull Corporation (NASDAQ: BULL), caught in the thick of allegations that have turned the investor community's...

Continue Reading
Fractal Sees Explosive Q2 Gain: Revenue Hits $100M

Updated Category News Views 93

Fractal’s Revenue Moment: Climbing New Peaks Fractal Analytics just knocked it out of the park, folks. Imagine this—an AI company pulling in $100 million for the first quarter, getting a 20% jump in revenue year on year. That's right, these numbers aren't just fancy figures; they're staggering proof that Fractal's hitting its AI stride. The healthcare and life...

Continue Reading
New Story Appoints Drudge, Celebrates Workplace Recognition

Updated Category News Views 0

A Dual Milestone: Leadership and Recognition In an industry chock-full of buzzwords, New Story’s latest moves cut through the noise. They've just announced Adam Drudge as their new Chief People Officer, and wouldn't you know it, they've snagged their third straight Most Loved Workplace® recognition for 2026. When a special ed company starts making waves like this,...

Continue Reading
Cerillion 26.2: New AI Powers & Open Standards Edge

Updated Category News Views 61

Leading the Charge in Telecom AI Ah, the telecom game—it's a battlefield and Cerillion’s just lobbed a game-changer onto the field with their 26.2 release. This ain’t your run-of-the-mill update; we're talking expanded agentic AI capabilities that are set to shake the very core of BSS/OSS solutions. AI Innovations That Matter No fluff here, just solid improvements....

Continue Reading
Systemair Wins First Natural Refrigerant Heat Pump Deal

Updated Category News Views 77

Systemair Breaks New Ground Hold onto your hats, because Systemair just sealed a deal that's going to make waves. Their recent accomplishment isn't just some humdrum business tedium—it's an intriguing step forward in the HVAC world. Systemair snagged their very first order for air handling units featuring an integrated heat pump and natural refrigerant. You've got to...

Continue Reading
Stellus Capital Set to Unveil Q3 Results: Key Details

Updated Category News Views 138

Stellus Capital's Upcoming Financial Reveal: Stakes and Details November's not just bringing the cold breezes, folks; it's also ushering in the much-anticipated financial digits of Stellus Capital Investment Corporation's third quarter of 2026. Mark your calendars for November 9, after the stock market wraps up, when Stellus will drop its operational performance stats for...

Continue Reading
LITE, RRC, SGRY: Are Shareholders Getting Shortchanged?

Updated Category News Views 51

What's Really Going On Here? Here's the skinny: Halper Sadeh LLC, that hard-hitting investor rights law firm, is poking their noses into some potential red flags over at a few companies you might have heard of—Lumentum Holdings (NASDAQ:LITE), Range Resources (NYSE:RRC), and Surgery Partners (NASDAQ:SGRY). They're sniffing around transactions that might leave the regular...

Continue Reading

Top 5 Most Recently Viewed Articles

Deloitte Finds Generative AI Revolutionizing Dealmaking Trends

Updated Category News Views 780

Deloitte Finds Generative AI Revolutionizing Dealmaking Trends While investment will continue to grow so will the expectation of tangible, near-term results. In a recent study, Deloitte announced insightful findings from its inaugural survey on Generative AI (GenAI) within the realm of mergers and acquisitions (M&A). The survey garnered responses from 1,000 leaders in...

Continue Reading
Consumer Insights on Biometrics Adoption and Trust Factors

Updated Category News Views 137

Growing Trust in Biometric Technology Among Consumers Biometric technology has gradually woven itself into our daily routines, with devices like smartphones and laptops frequently employing it for secure access. Recent findings indicate that over half of consumers now rely on biometric authentication every day, a trend that demonstrates significant confidence in this...

Continue Reading
Lamar Advertising Revises Projections Following Mixed Earnings

Updated Category News Views 223

Lamar Advertising Updates Earnings Guidance Lamar Advertising Company (NASDAQ: LAMR) has recently revealed its earnings for the second quarter, presenting a mixture of results that have prompted a reassessment by analysts. While the company reported earnings per share of $1.52, significantly surpassing the analyst consensus estimate of 86 cents, its revenue fell short of...

Continue Reading
Discover the Versatile iQ MiniOven by CHEF iQ for Your Kitchen

Updated Category News Views 293

Introducing the iQ MiniOven: A Revolution in Smart Cooking CHEF iQ has made a major leap in kitchen technology with the launch of the iQ MiniOven, a smart kitchen appliance designed to simplify cooking for the modern home chef. This compact yet powerful oven boasts 11 cooking functions and numerous intelligent presets, promising to streamline meal preparation and offer...

Continue Reading
AM Best Updates Credit Rating Outlook for Nonprofits Insurance Alliance

Updated Category News Views 207

AM Best Updates Credit Rating Outlook for Nonprofits Insurance Alliance AM Best has announced a revision to the outlook for the Long-Term Issuer Credit Ratings (ICRs) of members of the Nonprofits Insurance Alliance Group, adjusting it from stable to negative. This encompasses organizations like the Nonprofits Insurance Alliance of California, National Alliance of...

Continue Reading